Voriconazole-induced blistering in the setting of graft versus host disease: A report of 2 patients. J Am Acad Dermatol 2008 Mar;58(3):484-7
Date
02/19/2008Pubmed ID
18280346DOI
10.1016/j.jaad.2005.08.069Scopus ID
2-s2.0-38949186469 (requires institutional sign-in at Scopus site) 11 CitationsAbstract
Voriconazole is a newer triazole antifungal agent with a wide spectrum of activity against yeast, fungi and molds including many Candida, Aspergillus, and Fusarium species. Its use continues to increase, particularly in immunocompromised patients, owing to its broad coverage, availability in both intravenous and oral preparations, and safety profile. The detection of adverse events in these patients may be complicated by their preexisting comorbidities and polypharmacy. We describe 2 patients with hematologic malignancies status post allogeneic bone marrow transplantation who developed blistering eruptions on the extremities related to voriconazole use. A history of graft versus host disease in each patient confounded and delayed the diagnosis. It is imperative to recognize voriconazole-induced blistering as a separate and distinct entity in such patients with a history of graft versus host disease, since delayed withdrawal of voriconazole use could result in unnecessary and potentially dangerous increases in immunosuppressive therapy.
Author List
Conlon JD, Dauenhauer M, Tonkovic-Capin V, Talano J, Margolis D, Drolet BA, Fairley JAAuthors
David A. Margolis MD Chair, Professor in the Pediatrics department at Medical College of WisconsinJulie-An M. Talano MD Professor in the Pediatrics department at Medical College of Wisconsin
MESH terms used to index this publication - Major topics in bold
AdultAntifungal Agents
Blister
Bone Marrow Transplantation
Extremities
Female
Fusarium
Graft vs Host Disease
Humans
Male
Middle Aged
Mycoses
Pyrimidines
Triazoles
Voriconazole
